The life sciences sector faces headwinds amid rising real estate vacancies and cooling venture capital (VC) funding, particularly evident in the Greater Boston area where lab space vacancies have surged. Biopharma financing for the first seven months of 2025 totals $34.89 billion, a decline from 2024 but above post-pandemic levels. Amid these trends, some companies face stock devaluations due to operational challenges, while startups and established firms alike navigate a more cautious capital market. This environment underscores the sector’s ongoing transition after the pandemic-fueled expansion.